Top Markets
#1 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +18.57%
#2 Movement Movement +8.01%
#3 COTI COTI +7.56%
#4 DMT-NAT DMT-NAT +7.27%
#5 Victoria VR Victoria VR +7.18%
#6 GRVT Token GRVT Token +4.67%
#7 Cryptopia Cryptopia +3.74%
#8 Kinetiq Kinetiq +3.53%
#9 Lisk Lisk +3.28%
#10 Jito Jito +3.02%
Coin of the day
FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock)
Configuración
Idioma
ESPAñOL
Moneda
USD
Tema
Xeno Transplants Corporation Xeno Transplants Corporation

Xeno Transplants Corporation

XENO
Clasificación en acciones #42146
Xeno Transplants Corporation functions as a biotechnology firm dedicated to... Xeno Transplants Corporation functions as a biotechnology firm dedicated to research and development. Leveraging a specific licensing agreement with Massachusetts General Hospital, the company aims to innovate, produce, commercialize, and implement products and methodologies for public application in the field of xenotransplantation. The primary objective of this xenotransplantation research is to alleviate the critical scarcity of human cells, tissues, and organs required for medical transplants. This is achieved by pioneering techniques that enable the transfer of biological components—such as cells, tissues, and organs—from non-human species, including pigs, into human recipients. Established in 2004, Xeno Transplants Corporation maintains its headquarters in Brookline, Massachusetts.
Precio por acción
$0.0001
Última sincronización: 2026-08-11
Capitalización bursátil
$4.04K
Cambio (1 día)
0.00%
Cambio (1 año)
0.00%
País
CA
Comercio Xeno Transplants Corporation (XENO)

Categoría

Healthcare
Ingresos de Xeno Transplants Corporation (XENO)
Ingresos en Aug 2026 TTM: 0
Según los últimos informes financieros de Xeno Transplants Corporation, los ingresos actuales de la empresa (TTM) son 0. En 2026, la empresa obtuvo unos ingresos de 0 igual a los ingresos del año 2026, que fueron de 0. Los ingresos representan la cantidad total que una empresa genera por la venta de bienes o servicios. A diferencia de las ganancias, no se restan los gastos.
Historial de ingresos de Xeno Transplants Corporation desde 2026 hasta 2026
Ingresos al final de cada año
Año Ingresos Cambiar
Not enough data for the provided dates.
Ingresos de empresas similares o competidoras
Empresa Ingresos Diferencia de ingresos País
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $10.11B -
BE
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR